The future standard
for brucellosis vaccines
worldwide
GreenVac technology will revolutionise efficiency and standardisation in brucellosis control programs
Features
BGV1 is a remarkable vaccine, that is:
- New (under patent)
- Obtained by Rev1 gene deletion
- Consists of living bacteria
- Hightly attenuated
- Immunogenic & effective against infection
Benefits
Replaces Rev1, since BGV1 is:
- Safe, including with pregnant animals in mass vaccination
- Protective
- Compatible with D.I.V.A.
- Treatable with antibiotics
- Aplicable for uncomplicated control & eradication programmes
- Cost-effective, reducing financial impact in Public Health
Potential Unique Selling Point, to:-
Transform the lives of 600 million livestock holders in developing countries
